share_log

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial

銀屑病試驗中Piclidenoson數據公佈後，Can-Fite BioPharma股價跳漲
Benzinga Real-time News ·  2022/06/29 19:50
  • Can-Fite BioPharma Ltd (NYSE:CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis.
  • The study data show that patients treated with oral Piclidenoson 2 mg or 3 mg twice daily had clinically equivalent efficacy responses. 
  • At week 16, patients receiving Piclidenoson 3mg demonstrated statistically significant improvement compared with placebo, as measured by the Psoriasis Area and Severity Index (PASI) 75 response - Piclidenoson 3mg: 9.7% vs. placebo: 2.6%. 
  • Related: Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study.
  • Secondary endpoint parameters at week 32 comparing Piclidenoson to the active control drug, Amgen Inc's (NASDAQ:AMGN) Otezla (apremilast), revealed inferiority related to PASI 75 (17% vs. 26.2%) and PASI 50 (34.1% vs. 49.5%).
  • But revealed the superiority of Piclidenoson compared to Otezla in the Psoriasis Disability Index (PDI) (20.5% vs. 10.3%).
  • Piclidenoson showed a favorable safety profile.
  • Price Action: CANF shares are up 33.8% at $1.19 during the premarket session on the last check Wednesday.
  • 凱菲特生物製藥有限公司(紐約證券交易所市場代碼：CANF)宣佈了在400多名患有中到重度斑塊狀牛皮癬的成年人身上進行的Piclidenoson Comfort 3期試驗的TOPLINE結果。
  • 研究數據顯示，每日兩次口服2毫克或3毫克匹立地鬆的患者在臨牀上具有相同的療效。
  • 在第16周，服用3毫克匹利地鬆的患者與服用安慰劑的患者相比，表現出統計上的顯著改善，根據牛皮癬面積和嚴重程度指數(PASI)75反應--匹利地鬆3毫克：9.7%對安慰劑：2.6%。
  • 相關： 從銀屑病研究中讀取Piclidenoson數據時，Can-Fite BioPharma標記延遲.
  • 在第32周比較匹利地鬆和活性對照藥物的次要終點參數，安進納斯達克：AMGN)Otezla(Apremilast)，顯示出與PASI75(17%對26.2%)和PASI50(34.1%對49.5%)相關的劣勢。
  • 但與Otezla相比，Piclidenoson在牛皮癬殘疾指數(PDI)中的優勢(20.5%比10.3%)。
  • Piclidenoson顯示出良好的安全性。
  • 價格行動：在週三的盤前交易中，CANF的股價上漲了33.8%，至1.19美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論